Intervention

Mirabegron

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 17 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials17
Recruiting2
Common conditions25
Lead sponsors shown14
Advertisement

Clinical trials

17 shown
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyNCT06534762 · 2024-07-15
RECRUITING
Mechanisms for Activation of Beige Adipose Tissue in HumansNCT04666636 · 2020-12-07
RECRUITING
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With ObesityNCT05713799 · 2026-10-12
NOT_YET_RECRUITING
ADRB3 Signaling Pathway in Human Adipose TissueNCT05634174 · 2023-08-01
ACTIVE_NOT_RECRUITING
Activation of Brown Adipose Tissue Metabolism Using MirabegronNCT04823442 · 2021-01-21
COMPLETED
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized StudyNCT03600766 · 2018-08-01
UNKNOWN
Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's DiseaseNCT03412513 · 2017-07-17
UNKNOWN
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor AgonistsNCT03049462 · 2017-03-13
COMPLETED
Beta 3 Agonist Treatment in Heart Failure-2NCT03926754 · 2017-01-23
COMPLETED
Brown Fat Activation StudyNCT02919176 · 2016-09-01
COMPLETED
Mirabegron and Brown Adipose TissueNCT03012113 · 2016-06-01
UNKNOWN
Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart FailureNCT02775539 · 2016-06-01
UNKNOWN
Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young AdultsNCT02354807 · 2015-10-01
UNKNOWN
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder PatientsNCT02044510 · 2014-07-01
TERMINATED
Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple SclerosisNCT02086188 · 2014-05-01
COMPLETED
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)NCT02092181 · 2014-03-01
COMPLETED
Beta 3 Agonist Treatment in Heart FailureNCT01876433 · 2013-09-30
COMPLETED

Common conditions

Leading sponsors

Trial status mix

COMPLETED7
UNKNOWN5
RECRUITING2
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
TERMINATED1

Phase mix

PHASE29
PHASE44
PHASE12
PHASE32
EARLY_PHASE11
NA1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.